| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Weixiao Huang, Tao Zhang, Xiaodi Li, Leilei Gong, Yu Zhang, Chengcheng Luan, Qi Shan, Xiaosong Gu, Lili Zha. Intranasal administration of umbilical cord mesenchymal stem cell exosomes alleviates Parkinson's disease. Neuroscience. 2024-05-05. PMID:38705349. |
this disease is typically characterized by the formation of lewy bodies in multiple brain regions and dopaminergic neuronal loss in the substantia nigra pars compacta, resulting in non-motor symptoms (e.g., olfactory deficits) and motor dysfunction in the late stages. |
2024-05-05 |
2024-05-08 |
mouse |
| Weixiao Huang, Tao Zhang, Xiaodi Li, Leilei Gong, Yu Zhang, Chengcheng Luan, Qi Shan, Xiaosong Gu, Lili Zha. Intranasal administration of umbilical cord mesenchymal stem cell exosomes alleviates Parkinson's disease. Neuroscience. 2024-05-05. PMID:38705349. |
finally, the activity of olfactory bulb neurons was improved and the loss of dopaminergic neurons in the substantia nigra pars compacta was reversed. |
2024-05-05 |
2024-05-08 |
mouse |
| Sheng Li, Yanbing Liu, Sen Lu, Jiayi Xu, Xiaokun Liu, Di Yang, Yuxuan Yang, Lin Hou, Ning L. A crazy trio in Parkinson's disease: metabolism alteration, α-synuclein aggregation, and oxidative stress. Molecular and cellular biochemistry. 2024-04-16. PMID:38625515. |
parkinson's disease (pd) is an aging-associated neurodegenerative disorder, characterized by the progressive loss of dopaminergic neurons in the pars compacta of the substantia nigra and the presence of lewy bodies containing α-synuclein within these neurons. |
2024-04-16 |
2024-04-18 |
Not clear |
| Lara Cheslow, Matthew Byrne, Jessica S Kopenhaver, Lorraine Iacovitti, Richard J Smeyne, Adam E Snook, Scott A Waldma. GUCY2C signaling limits dopaminergic neuron vulnerability to toxic insults. NPJ Parkinson's disease. vol 10. issue 1. 2024-04-13. PMID:38615030. |
mitochondrial dysfunction and reactive oxygen species (ros) accumulation within the substantia nigra pars compacta (snpc) are central drivers of dopaminergic (da) neuron death in parkinson's disease (pd). |
2024-04-13 |
2024-04-16 |
mouse |
| Cui Liu, Wen-Hong Liu, Wu Yang, Lei Chen, Yan Xue, Xin-Yi Che. GLP-1 modulated the firing activity of nigral dopaminergic neurons in both normal and parkinsonian mice. Neuropharmacology. 2024-04-10. PMID:38599494. |
although morphological studies revealed the expression of glp-1 receptors (glp-1rs) in the substantia nigra pars compacta, the possible modulation of glp-1 on spontaneous firing activity of nigral dopaminergic neurons is unknown. |
2024-04-10 |
2024-04-13 |
mouse |
| Sarah Hui, Jimmy George, Minesh Kapadia, Hien Chau, Zahn Bariring, Rebecca Earnshaw, Kashfia Shafiq, Lorraine V Kalia, Suneil K Kali. Mitophagy Upregulation Occurs Early in the Neurodegenerative Process Mediated by α-Synuclein. Molecular neurobiology. 2024-04-06. PMID:38581539. |
parkinson's disease (pd) is a progressive neurogenerative movement disorder characterized by dopaminergic cell death within the substantia nigra pars compacta (snpc) due to the aggregation-prone protein α-synuclein. |
2024-04-06 |
2024-04-10 |
human |
| Emre Uygur, Kadriye Büşra Karatay, Emine Derviş, Vedat Evren, Ayfer Yurt Kılçar, Özge Kozguş Güldü, Ceren Sezgin, Burcu Acar Çinleti, Volkan Tekin, Fazilet Zumrut Biber Muftule. Synthesis of Novel Plant-Derived Encapsulated Radiolabeled Compounds for the Diagnosis of Parkinson's Disease and the Evaluation of Biological Effects with In Vitro/In Vivo Methods. Molecular neurobiology. 2024-04-03. PMID:38568418. |
it is characterized by the loss of dopaminergic neurons in substantia nigra pars compacta (snc) and striatum. |
2024-04-03 |
2024-04-05 |
Not clear |
| Seong-Jin Yu, Yun Wang, Hui Shen, Eun-Kyung Bae, Yazhou Li, Kumar Sambamurti, Michael A Tones, Margaret M Zaleska, Barry J Hoffer, Nigel H Grei. DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson's disease. GeroScience. 2024-04-02. PMID:38563864. |
pre-treatment with oral sitagliptin or pf-00734,200 reduced methamphetamine (meth)-induced rotation post-lesioning and dopaminergic degeneration in lesioned substantia nigra pars compacta (snc) and striatum. |
2024-04-02 |
2024-04-04 |
human |
| Maya Molinari, Ori J Lieberman, David Sulzer, Emanuela Santini, Anders Borgkvis. 5-HT1B receptors mediate dopaminergic inhibition of vesicular fusion and GABA release from striatonigral synapses. bioRxiv : the preprint server for biology. 2024-04-01. PMID:38559006. |
the substantia nigra pars reticulata (snr), a crucial basal ganglia output nucleus, contains a dense expression of dopamine d1 receptors (d1rs), along with dendrites belonging to dopaminergic neurons of substantia nigra pars compacta. |
2024-04-01 |
2024-04-04 |
Not clear |
| Jindong Zhao, Ji Wang, Kunying Zhao, Yuxiao Zhang, Weiyan H. Protopanaxadiols Eliminate Behavioral Impairments and Mitochondrial Dysfunction in Parkinson's Disease Mice Model. Neurochemical research. 2024-03-29. PMID:38551796. |
currently, there are no effective therapies to cure parkinson's disease (pd), which is the second most common neurodegenerative disease primarily characterized by motor dysfunction and degeneration of dopaminergic neurons in the substantia nigra pars compacta (snc). |
2024-03-29 |
2024-04-01 |
mouse |
| Bandar Alharbi, Hayder M Al-Kuraishy, Ali I Al-Gareeb, Engy Elekhnawy, Hind Alharbi, Athanasios Alexiou, Marios Papadakis, Gaber El-Saber Batih. Role of GABA pathway in motor and non-motor symptoms in Parkinson's disease: a bidirectional circuit. European journal of medical research. vol 29. issue 1. 2024-03-28. PMID:38539252. |
parkinson's disease (pd) is a progressive neurodegenerative disease as a result of the degeneration of dopaminergic neurons in the substantia nigra pars compacta (snpc). |
2024-03-28 |
2024-03-30 |
Not clear |
| Wenjing Dong, Shuyi Liu, Shangang Li, Zhengbo Wan. Cell reprogramming therapy for Parkinson's disease. Neural regeneration research. vol 19. issue 11. 2024-03-25. PMID:38526281. |
parkinson's disease is typically characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta. |
2024-03-25 |
2024-03-27 |
human |
| Sina Hembach, Sebastian Schmidt, Tanja Orschmann, Ingo Burtscher, Heiko Lickert, Florian Giesert, Daniela Vogt Weisenhorn, Wolfgang Wurs. Engrailed 1 deficiency induces changes in ciliogenesis during human neuronal differentiation. Neurobiology of disease. 2024-03-22. PMID:38518837. |
a key pathological feature of parkinson's disease (pd) is the progressive degeneration of dopaminergic neurons (dans) in the substantia nigra pars compacta. |
2024-03-22 |
2024-03-25 |
mouse |
| Somdutta Das, Harshal Ramtek. A Comprehensive Review of the Role of Biomarkers in Early Diagnosis of Parkinson's Disease. Cureus. vol 16. issue 2. 2024-03-19. PMID:38500934. |
parkinson's disease (pd) is a complex neurological, degenerative clinical condition depicted by the advancing loss of dopaminergic neurons in the substantia nigra pars compacta, which manifests itself as a myriad of sensorimotor and non-motor signs in patients. |
2024-03-19 |
2024-03-21 |
Not clear |
| Wan-Hsuan Chang, Hung-Te Hsu, Chih-Cheng Lin, Li-Mei An, Chien-Hsing Lee, Horng-Huey Ko, Chih-Lung Lin, Yi-Ching L. Linalool, a Fragrance Compound in Plants, Protects Dopaminergic Neurons and Improves Motor Function and Skeletal Muscle Strength in Experimental Models of Parkinson's Disease. International journal of molecular sciences. vol 25. issue 5. 2024-03-13. PMID:38473763. |
parkinson's disease (pd) is a common neurodegenerative disorder characterized by the gradual loss of dopaminergic neurons in the substantia nigra pars compacta (snpc), resulting in reduced dopamine levels in the striatum and eventual onset of motor symptoms. |
2024-03-13 |
2024-03-15 |
Not clear |
| Kandatege Wimalasena, Oluwatosin Adetuyi, Maya Eldan. Metabolic energy decline coupled dysregulation of catecholamine metabolism in physiologically highly active neurons: implications for selective neuronal death in Parkinson's disease. Frontiers in aging neuroscience. vol 16. 2024-03-07. PMID:38450382. |
parkinson's disease (pd) is an age-related irreversible neurodegenerative disease which is characterized as a progressively worsening involuntary movement disorder caused by the loss of dopaminergic (da) neurons in substantia nigra pars compacta (snpc). |
2024-03-07 |
2024-03-09 |
Not clear |
| Yayun Yan, Mengchao Zhang, Wenhua Ren, Xiaoqi Zheng, Ying Chan. Neuromelanin-sensitive magnetic resonance imaging: Possibilities and promises as an imaging biomarker for Parkinson's disease. The European journal of neuroscience. 2024-03-05. PMID:38441250. |
parkinson's disease (pd) is an age-related progressive neurodegenerative disorder characterized by both motor and non-motor symptoms resulting from the death of dopaminergic neurons in the substantia nigra pars compacta (snpc) and noradrenergic neurons in the locus coeruleus (lc). |
2024-03-05 |
2024-03-07 |
Not clear |
| Inam Ullah, Shahab Uddin, Longhe Zhao, Xin Wang, Hongyu L. Autophagy and UPS pathway contribute to nicotine-induced protection effect in Parkinson's disease. Experimental brain research. 2024-03-02. PMID:38430248. |
degeneration of dopaminergic (da) neurons and buildup of the protein α-synuclein (α-syn) in the substantia nigra pars compacta (snpc) are two major causes of this disorder. |
2024-03-02 |
2024-03-04 |
caenorhabditis_elegans |
| Alagudurai Krishnamoorthy, Riddhi Upadhyay, Murugan Sevana. Chrysin for Neurotrophic and Neurotransmitter Balance in Parkinson's Disease. Methods in molecular biology (Clifton, N.J.). vol 2761. 2024-03-01. PMID:38427256. |
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (mptp) has a direct impact on the dopaminergic neurons in the substantia nigra pars compacta (snpc), dopamine in the striatum (st), homovanillic acid (hva), neurotrophic factors of the snpc, and st regions leading to parkinson's disease (pd). |
2024-03-01 |
2024-03-03 |
mouse |
| Sonia Dhiman, Ashi Mannan, Ayushi Taneja, Maneesh Mohan, Thakur Gurjeet Sing. Sirtuin dysregulation in Parkinson's disease: Implications of acetylation and deacetylation processes. Life sciences. 2024-03-01. PMID:38428569. |
parkinson's disease (pd) is a progressive neurodegenerative condition that primarily affects motor function and is caused by a gradual decline of dopaminergic neurons in the brain's substantia pars compacta (snpc) region. |
2024-03-01 |
2024-03-04 |
Not clear |